Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease

Conclusion: MAJESTIC results showed that patients whose femoropopliteal arteries were treated with the Eluvia drug-eluting stent sustained high patency and low MAE rates through 12 months.

Source: Journal of Endovascular Therapy - September 12, 2016 Category: Surgery Authors: Müller-Hülsbeck, S., Keirse, K., Zeller, T., Schroë, H., Diaz-Cartelle, J. Tags: Lower and Upper Limb Interventions Source Type: research